The UCLA AIDS Prevention and Treatment Clinical Trials Unit (UCLA-APT-CTU) is a multidisciplinary research unit composed of a core administrative unit and four clinical research sites in metropolitan Los Angeles. The investigative team has over 15 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies. Under the leadership of Judith Currier MD, MSc and a senior investigator team including Thomas Coates, PhD, Ronald Mitsuyasu, MD, Eric Daar, MD, Cathy Reback, Ph D, Steve Shoptaw, PhD and Stephen Brown MD, the unit will participate in the design and conduct of studies addressing the following four priority research areas; Prevention of HIV Infection, Translational Research/Drug Development, Optimization of Clinical Management, and Vaccine Research and Development in collaboration with the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HTPN) and the Vaccine Trials Network (VTN). The CTU has an administrative core and clinical research site at the UCLA Center for Clinical AIDS Research and Education (CARE Center) and additional Clinical Research Sites (CRS) at Harbor UCLA Medical Center and Friends Research Institute/Integrated Substance Abuse Program (ISAP) UCLA and AIDS Research Alliance.
The specific aims of our unit are to: 1. Evaluate new and potentially more effective HIV treatments. 2. Evaluate strategies for optimal use of antiretroviral therapies (ARV) in diverse populations. 3. Evaluate strategies to optimize the management of HIV infection and related co-morbidities. 4. Investigate HIV vaccines for therapy and for prevention of HIV infection. 5. Evaluate novel strategies for prevention of HIV infection in high-risk stimulant and injection drug users. 6. Evaluate strategies using ARV to prevent HIV acquisition. 7. Assess the role of early interventions in acutely infected individuals on long-term outcomes and transmission rates. 8. Mentor new minority investigators in cross-disciplinary HIV/AIDS research. 9. Make significant contributions to the leadership of the ACTG, HPTN and VTN through participation in the group leadership, scientific committees and protocol teams. 10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069424-07
Application #
8402573
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M2))
Program Officer
Bupp, Jane E
Project Start
2007-02-01
Project End
2013-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
7
Fiscal Year
2013
Total Cost
$2,494,558
Indirect Cost
$425,218
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hermanstyne, Keith A; Green Jr, Harold D; Cook, Ryan et al. (2018) Social Network Support and Decreased Risk of Seroconversion in Black MSM: Results of the BROTHERS (HPTN 061) Study. J Acquir Immune Defic Syndr 78:163-168
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Kelesidis, Theodoros; Moser, Carlee B; Johnston, Elizabeth et al. (2018) Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr 78:362-366
Stringer, Elizabeth M; Kendall, Michelle A; Lockman, Shahin et al. (2018) Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. PLoS One 13:e0199555
Tracy, LaRee A; Struble, Kimberly; Firnhaber, Cynthia et al. (2018) Age Differences by Sex in Antiretroviral-Naïve Participants: Pooled Analysis from Randomized Clinical Trials. J Assoc Nurses AIDS Care 29:371-382
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Kelesidis, Theodoros; Kendall, Michelle A; Danoff, Ann et al. (2018) Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332. Medicine (Baltimore) 97:e10955

Showing the most recent 10 out of 165 publications